COIOSDeep risk insights through multi-disciplinary research across the globe
a close up of a sign on a building
Item confirms Peer-reviewed Added

Low-dose rivaroxaban and mortality in coronary artery disease, pooled from five trials

Across five randomised trials in coronary artery disease, low-dose rivaroxaban was linked to lower all-cause mortality than standard antithrombotic therapy.

This meta-analysis compared low-dose rivaroxaban with standard antithrombotic therapy across the spectrum of coronary artery disease. It pooled five randomised controlled trials, with 37 709 patients, found through MEDLINE, EMBASE, Cochrane and meeting proceedings. All-cause mortality was lower with rivaroxaban (incidence rate ratio [IRR] 0.83, 95% CI 0.70-0.98), driven by cardiovascular mortality (IRR 0.82). Myocardial infarction (IRR 0.88) and stroke (IRR 0.71) were also reduced. Ischaemic stroke was also lower (IRR 0.60), with no offsetting rise in haemorrhagic stroke. Major bleeding rose (IRR 1.46), though its interval of 0.99-2.17 included no effect, and fatal bleeding did not rise.

Why it is interesting: The pooled trials show a fall in deaths, not only in heart attacks and strokes. That fall in deaths came with more major bleeding, though fatal bleeding did not rise.

Source
Journal of Invasive Cardiology, 20 November 2026
Paper
Reduced mortality with low-dose rivaroxaban in patients with coronary artery disease: a meta-analysis
Authors
Palmerini T, Nardi E, Lezzi M, Bruno AG, Lombardi L, Chi G et al.
DOI
10.25270/jic/26.00286
Type
Peer-reviewed article
Design
Meta-analysis of 5 randomised controlled trials, 37,709 patients, low-dose rivaroxaban vs standard antithrombotic therapy in coronary artery disease
Verdict
Confirms prior evidence
Driver
Heart and stroke

Other drivers in Health today